2358-2359 / 2953
RT01 trial: 5-year follow-up:
Improved bPFS with dose-escalation (44% high risk)
Median follow-up: 5
years
Standard dose CFRT
64 Gy/32 fractions
(n=421)
Escalated-dose CFRT
74 Gy/37 fractions
(n=422)
HR (95% CI)
bPFS at 5 years
60%
71%
0.67 (0.53-0.85) p<0.0007
bPFS events
149
108
Clinical PFS
87%
90%
0.69 (0.47-1.02) p=0.064
Freedom from
80%
84%
0.78 (0.57-1.07) p=0.12
salvage androgen
suppression
19
bPFS, biochemical progression-free survival; CFRT, conformal radiotherapy; HR, hazard ratio; all comparisons expressed relative
to patients in standard group (i.e. HR <1
・
0 indicates decreased risk of event for escalated group)
Dearnaley DP et al. Lancet Oncol 2007;8:475–87
At 5 years, using CFRT to increase RT dose from 64 Gy to 74 Gy had substantially improved
prostate-cancer control in terms of bPFS